Elevated whole blood chemiluminescence in patients with systemic sclerosis. 2005

M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
Department of Experimental and Clinical Physiology, Institute of Physiology and Biochemistry, Medical University of Lodz, Lodz, Poland.

OBJECTIVE Systemic sclerosis (SSc) is accompanied by oxidative stress that in turn may accelerate endothelium degeneration and thus disease progression. We tested whether phagocytes from SSc patients release more reactive oxygen species (ROS) and whether this release correlates with some clinical parameters. METHODS ROS production by blood phagocytes was measured with the luminol enhanced whole blood chemiluminescence (CL). Resting and N-formyl-methionyl-leucyl-phenylalanine -induced CL (fMLP-induced CL) was measured in 30 patients with SSc and 30 healthy controls matched as to age, sex, and level of cigarette smoking. RESULTS Resting CL and fMLP-induced CL calculated per 10(4) phagocytes present in the assayed blood sample were higher in patients with systemic sclerosis than in healthy controls (median; range, 0.88; 0.47-1.39 vs. 0.73; 0.13-1.07 aU/10(4)p and 621; 293-3522 vs. 411; 289-810 aUxs/10(4)p, p<0.02). Patients treated with cyclophosphamide and/or prednisone for 11; 3-168 months did not differ in respect to CL from those that never received the medications. Similarly, no significant differences were found between patients with limited and diffuse SSc. Resting CL correlated (p<0.05) with clinically manifested interstitial lung disease (r=0.59), single breath carbon monoxide diffusing capacity (r= -0.56) and serum autoantibodies titre (r= 0.43). CONCLUSIONS Blood phagocytes from patients with systemic sclerosis, especially from those with interstitial lung disease, generate elevated amounts of ROS as assessed with CL. This confirms the presence of systemic oxidative stress in SSc patients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008163 Luminescent Measurements Techniques used for determining the values of photometric parameters of light resulting from LUMINESCENCE. Bioluminescence Measurements,Bioluminescent Assays,Bioluminescent Measurements,Chemiluminescence Measurements,Chemiluminescent Assays,Chemiluminescent Measurements,Chemoluminescence Measurements,Luminescence Measurements,Luminescent Assays,Luminescent Techniques,Phosphorescence Measurements,Phosphorescent Assays,Phosphorescent Measurements,Assay, Bioluminescent,Assay, Chemiluminescent,Assay, Luminescent,Assay, Phosphorescent,Assays, Bioluminescent,Assays, Chemiluminescent,Assays, Luminescent,Assays, Phosphorescent,Bioluminescence Measurement,Bioluminescent Assay,Bioluminescent Measurement,Chemiluminescence Measurement,Chemiluminescent Assay,Chemiluminescent Measurement,Chemoluminescence Measurement,Luminescence Measurement,Luminescent Assay,Luminescent Measurement,Luminescent Technique,Measurement, Bioluminescence,Measurement, Bioluminescent,Measurement, Chemiluminescence,Measurement, Chemiluminescent,Measurement, Chemoluminescence,Measurement, Luminescence,Measurement, Luminescent,Measurement, Phosphorescence,Measurement, Phosphorescent,Measurements, Bioluminescence,Measurements, Bioluminescent,Measurements, Chemiluminescence,Measurements, Chemiluminescent,Measurements, Chemoluminescence,Measurements, Luminescence,Measurements, Luminescent,Measurements, Phosphorescence,Measurements, Phosphorescent,Phosphorescence Measurement,Phosphorescent Assay,Phosphorescent Measurement,Technique, Luminescent,Techniques, Luminescent
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009240 N-Formylmethionine Leucyl-Phenylalanine A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. F-Met-Leu-Phe,N-Formyl-Methionyl-Leucyl-Phenylalanine,Formylmet-Leu-Phe,Formylmethionyl Peptide,Formylmethionyl-Leucyl-Phenylalanine,Formylmethionylleucylphenylalanine,N-Formylated Peptide,N-formylmethionyl-leucyl-phenylalanine,fMet-Leu-Phe,F Met Leu Phe,Formylmet Leu Phe,Formylmethionyl Leucyl Phenylalanine,Leucyl-Phenylalanine, N-Formylmethionine,N Formyl Methionyl Leucyl Phenylalanine,N Formylated Peptide,N Formylmethionine Leucyl Phenylalanine,N formylmethionyl leucyl phenylalanine,Peptide, Formylmethionyl,Peptide, N-Formylated,fMet Leu Phe
D010586 Phagocytes Cells that can carry out the process of PHAGOCYTOSIS. Phagocyte,Phagocytic Cell,Phagocytic Cells,Cell, Phagocytic,Cells, Phagocytic
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011653 Pulmonary Diffusing Capacity The amount of a gas taken up, by the pulmonary capillary blood from the alveolar gas, per minute per unit of average pressure of the gradient of the gas across the BLOOD-AIR BARRIER. Capacity, Pulmonary Diffusing,Diffusing Capacity, Pulmonary
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D002248 Carbon Monoxide Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed) Monoxide, Carbon

Related Publications

M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
January 2009, Interactive cardiovascular and thoracic surgery,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
June 1989, Zeitschrift fur Stomatologie (1984),
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
August 1993, British journal of haematology,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
November 1994, The Journal of allergy and clinical immunology,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
March 2004, The Journal of rheumatology,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
January 2005, Arthritis research & therapy,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
January 1988, Clinical and experimental rheumatology,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
January 1993, Scandinavian journal of rheumatology,
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
March 1986, Clinical science (London, England : 1979),
M Luczynska, and U Szkudlarek, and B Dziankowska-Bartkowiak, and E Waszczykowska, and M Kasielski, and G Jozefowicz-Okonkwo, and D Nowak
August 1990, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!